Gastrointestinal Cancers (Issue 5)

One gene can encode more than one protein; however, proteins are dynamic (binding to membranes, other proteins, synthesis, degradation), undergo co- and post-translational modification, and exist in a wide range of concentrations in the body.

In a 2015, retrospective single-center study, patients with advanced HCC received systemic therapy with sorafenib combined with transarterial chemoembolization (TACE), and outcomes were compared between elderly (>70 years) and nonelderly (<70 years) patients.

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.

New agents that focus on the duplication of HCV are poised to majorly impact the prevention and recurrence of HCC, as well as show the ability to reverse liver fibrosis and cirrhosis in the treatment of patients with end-stage HCC.

Results of a large expanded access program, presented at the 2015 World Congress on GI Cancer, confirmed the efficiency and safety of regorafenib (Stivarga) in previously treated patients with mCRC.

Josep Tabernero, MD, PhD, gave a synopsis, in a talk at the 2015 World Congress on GI Cancer, of novel agents that are under examination for the treatment of patients with gastric cancer.